Subthreshold laser therapy for diabetic macular edema: Metabolic and safety issues

Stela Vujosevic, Ferdinando Martini, Enrica Convento, Evelyn Longhin, Olympia Kotsafti, Raffaele Parrozzani, Edoardo Midena

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose: To review the most important metabolic effects and clinical safety data of subthreshold micropulse diode laser (D-MPL) in diabetic macular edema (DME). Methods: Review of the literature about the mechanisms of action and role of D-MPL in DME. Results: The MPL treatment does not damage the retina and is selectively absorbed by the retinal pigment epithelium (RPE). MPL stimulates secretion of different protective cytokines by the RPE. No visible laser spots on the retina were noted on any fundus image modality in different studies, and there were no changes of the outer retina integrity. Mean central retinal sensitivity (RS) increased in subthreshold micropulse diode laser group compared to standard ETDRS photocoagulation group. Conclusions: MPL is a new, promising treatment option in DME, with both infrared and yellow wavelengths using the less aggressive duty cycle (5%) and fixed power parameters. It appears to be safe from morphologic and functional point of view in mild center involving DME.

Original languageEnglish
Pages (from-to)3267-3271
Number of pages5
JournalCurrent Medicinal Chemistry
Volume20
Issue number26
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Retinal Pigments
Macular Edema
Laser Therapy
Semiconductor lasers
Safety
Retina
Semiconductor Lasers
Retinal Pigment Epithelium
Lasers
Cytokines
Infrared radiation
Wavelength
Light Coagulation
Therapeutics

Keywords

  • Diabetic macular edema
  • Diabetic retinopathy
  • Fluorescein angiography
  • Fundus autofluorescence
  • Laser treatment
  • Microperimetry
  • Optical coherence tomography
  • Retinal safety
  • Subthreshold micropulse laser

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Vujosevic, S., Martini, F., Convento, E., Longhin, E., Kotsafti, O., Parrozzani, R., & Midena, E. (2013). Subthreshold laser therapy for diabetic macular edema: Metabolic and safety issues. Current Medicinal Chemistry, 20(26), 3267-3271. https://doi.org/10.2174/09298673113209990030

Subthreshold laser therapy for diabetic macular edema : Metabolic and safety issues. / Vujosevic, Stela; Martini, Ferdinando; Convento, Enrica; Longhin, Evelyn; Kotsafti, Olympia; Parrozzani, Raffaele; Midena, Edoardo.

In: Current Medicinal Chemistry, Vol. 20, No. 26, 09.2013, p. 3267-3271.

Research output: Contribution to journalArticle

Vujosevic, S, Martini, F, Convento, E, Longhin, E, Kotsafti, O, Parrozzani, R & Midena, E 2013, 'Subthreshold laser therapy for diabetic macular edema: Metabolic and safety issues', Current Medicinal Chemistry, vol. 20, no. 26, pp. 3267-3271. https://doi.org/10.2174/09298673113209990030
Vujosevic S, Martini F, Convento E, Longhin E, Kotsafti O, Parrozzani R et al. Subthreshold laser therapy for diabetic macular edema: Metabolic and safety issues. Current Medicinal Chemistry. 2013 Sep;20(26):3267-3271. https://doi.org/10.2174/09298673113209990030
Vujosevic, Stela ; Martini, Ferdinando ; Convento, Enrica ; Longhin, Evelyn ; Kotsafti, Olympia ; Parrozzani, Raffaele ; Midena, Edoardo. / Subthreshold laser therapy for diabetic macular edema : Metabolic and safety issues. In: Current Medicinal Chemistry. 2013 ; Vol. 20, No. 26. pp. 3267-3271.
@article{39f043ad760e411493a67f1d757a1c1b,
title = "Subthreshold laser therapy for diabetic macular edema: Metabolic and safety issues",
abstract = "Purpose: To review the most important metabolic effects and clinical safety data of subthreshold micropulse diode laser (D-MPL) in diabetic macular edema (DME). Methods: Review of the literature about the mechanisms of action and role of D-MPL in DME. Results: The MPL treatment does not damage the retina and is selectively absorbed by the retinal pigment epithelium (RPE). MPL stimulates secretion of different protective cytokines by the RPE. No visible laser spots on the retina were noted on any fundus image modality in different studies, and there were no changes of the outer retina integrity. Mean central retinal sensitivity (RS) increased in subthreshold micropulse diode laser group compared to standard ETDRS photocoagulation group. Conclusions: MPL is a new, promising treatment option in DME, with both infrared and yellow wavelengths using the less aggressive duty cycle (5{\%}) and fixed power parameters. It appears to be safe from morphologic and functional point of view in mild center involving DME.",
keywords = "Diabetic macular edema, Diabetic retinopathy, Fluorescein angiography, Fundus autofluorescence, Laser treatment, Microperimetry, Optical coherence tomography, Retinal safety, Subthreshold micropulse laser",
author = "Stela Vujosevic and Ferdinando Martini and Enrica Convento and Evelyn Longhin and Olympia Kotsafti and Raffaele Parrozzani and Edoardo Midena",
year = "2013",
month = "9",
doi = "10.2174/09298673113209990030",
language = "English",
volume = "20",
pages = "3267--3271",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "26",

}

TY - JOUR

T1 - Subthreshold laser therapy for diabetic macular edema

T2 - Metabolic and safety issues

AU - Vujosevic, Stela

AU - Martini, Ferdinando

AU - Convento, Enrica

AU - Longhin, Evelyn

AU - Kotsafti, Olympia

AU - Parrozzani, Raffaele

AU - Midena, Edoardo

PY - 2013/9

Y1 - 2013/9

N2 - Purpose: To review the most important metabolic effects and clinical safety data of subthreshold micropulse diode laser (D-MPL) in diabetic macular edema (DME). Methods: Review of the literature about the mechanisms of action and role of D-MPL in DME. Results: The MPL treatment does not damage the retina and is selectively absorbed by the retinal pigment epithelium (RPE). MPL stimulates secretion of different protective cytokines by the RPE. No visible laser spots on the retina were noted on any fundus image modality in different studies, and there were no changes of the outer retina integrity. Mean central retinal sensitivity (RS) increased in subthreshold micropulse diode laser group compared to standard ETDRS photocoagulation group. Conclusions: MPL is a new, promising treatment option in DME, with both infrared and yellow wavelengths using the less aggressive duty cycle (5%) and fixed power parameters. It appears to be safe from morphologic and functional point of view in mild center involving DME.

AB - Purpose: To review the most important metabolic effects and clinical safety data of subthreshold micropulse diode laser (D-MPL) in diabetic macular edema (DME). Methods: Review of the literature about the mechanisms of action and role of D-MPL in DME. Results: The MPL treatment does not damage the retina and is selectively absorbed by the retinal pigment epithelium (RPE). MPL stimulates secretion of different protective cytokines by the RPE. No visible laser spots on the retina were noted on any fundus image modality in different studies, and there were no changes of the outer retina integrity. Mean central retinal sensitivity (RS) increased in subthreshold micropulse diode laser group compared to standard ETDRS photocoagulation group. Conclusions: MPL is a new, promising treatment option in DME, with both infrared and yellow wavelengths using the less aggressive duty cycle (5%) and fixed power parameters. It appears to be safe from morphologic and functional point of view in mild center involving DME.

KW - Diabetic macular edema

KW - Diabetic retinopathy

KW - Fluorescein angiography

KW - Fundus autofluorescence

KW - Laser treatment

KW - Microperimetry

KW - Optical coherence tomography

KW - Retinal safety

KW - Subthreshold micropulse laser

UR - http://www.scopus.com/inward/record.url?scp=84883237476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883237476&partnerID=8YFLogxK

U2 - 10.2174/09298673113209990030

DO - 10.2174/09298673113209990030

M3 - Article

C2 - 23745552

AN - SCOPUS:84883237476

VL - 20

SP - 3267

EP - 3271

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 26

ER -